论文部分内容阅读
目的评价多西他赛联合奈达铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法经病理组织学证实为晚期非小细胞肺癌的58例患者接受多西他赛联合奈达铂方案化疗。结果 58例患者共接受263个周期的化疗,总有效率44.8%,不良反应主要为骨髓抑制,无相关死亡毒性。结论该方案作为姑息化疗用于晚期非小细胞肺癌有较好的疗效,且不良反应基本可以耐受,安全性较好。
Objective To evaluate the clinical efficacy and safety of docetaxel combined with nedaplatin in the treatment of advanced non-small cell lung cancer (NSCLC). METHODS: Fifty-eight patients with advanced non-small cell lung cancer confirmed by histopathology underwent docetaxel plus nedaplatin chemotherapy. Results 58 patients received a total of 263 cycles of chemotherapy, the total effective rate was 44.8%. Adverse reactions were mainly myelosuppression with no related death toxicity. Conclusion As a palliative chemotherapy, this regimen has good curative effect in advanced non-small cell lung cancer and its adverse reactions are basically tolerable and safe.